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Low birthweight due to intrauterine growth restriction is associated with metabolic 
disorders after birth. Our 1st study assessed deficits in skeletal muscle glucose metabolism and 
pancreatic β cell function in IUGR fetal sheep. We aimed to evaluate the effectiveness of daily 
intravenous infusions of the anti-inflammatory ω-3 polyunsaturated fatty acid (PUFA), 
eicosapentaenoic acid (EPA), as a means of improving deficits previously observed in the IUGR 
fetus by targeting fetal systemic inflammation. The presence of systemic inflammation in IUGR 
fetuses was evident by increased total circulating populations of total leukocytes, lymphocytes, 
and monocytes. However, these were decreased by 5-day ω-3 PUFA infusions. Additional blood 
parameters including lactate and CO2 were increased in IUGR fetuses, regardless of infusion of 
EPA. Poor β cell function in IUGR fetuses was improved by EPA infusion, as evident by 
improved circulating plasma insulin, O2, CO2, HCO3, Na+, K+, and Cl- during a hyperglycemic 
clamp. Hindlimb glucose uptake and oxidation rates, which were impaired by IUGR were 
improved by EPA infusion as well. These findings indicate that targeting systemic fetal 
inflammation by infusion of the anti-inflammatory ω-3 PUFA, EPA, many IUGR-associated 








Our 2nd study sought to determine the effectiveness of daily EPA infusions on fetal 
growth biometrics and skeletal muscle-specific deficits associated with IUGR. In IUGR fetuses, 
decrease in mass were observed for whole fetus, hindlimb, semitendinosus, soleus, longissimus 
dorsi, lungs, and kidneys, but 5-day EPA infusion improved most of these deficits. The fiber 
type ratios of skeletal muscle estimated by myosin heavy chain proportions were also altered by 
IUGR but were recovered by EPA infusion as well. Ex vivo glucose uptake and oxidation 
capacities were impaired in IUGR muscle but were improved after daily EPA infusions. Results 
from this study indicate that daily fetal ω-3 PUFA infusions of EPA were effective in improving 
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The physiological response to any external stimulus defines the result to that event. Whether to 
everyday life events or catastrophic insults, bodily responses to events define how life will move 
forward. Everitt (1968) discussed the extent to which future responses are altered by events that 
occur during fetal development. Subsequent epidemiological studies have defined the concept of 
fetal programming and the thrifty metabolic phenotype hypothesis was established in the early 
1990’s (Hales and Barker, 1992; Godfrey and Barker, 2000). The building literature in this field 
show that detrimental effects of maternal stress during critical windows of fetal development 
cannot be overstated. Intrauterine growth restriction (IUGR) is the phenotypic result of poor 
intrauterine conditions causing nutrient-sparing metabolic and growth deficits that predispose 
individuals to a multitude of metabolic disorders (Thorne et al., 2014; Brown et al., 2015). Fetal 
adaptations occur to aid fetal survival but the repartitioning of fetal nutrients toward vital organs 
and tissues occurs at the expense of fetal growth and glucose homeostasis (Yates et al., 2014; 
Yates et al., 2018). Using the well-characterized heat stress model for placental insufficiency 
induced IUGR (PI-IUGR) in the ovine, we have previously reported links between adrenergic 
and inflammatory signaling pathways, reduced fetal growth, and metabolic inefficacy (Cadaret et 
al., 2019a; Posont and Yates, 2019). We also found that post-natal supplementation yielded 
increased body performance in IUGR-born offspring. Although this provides a basis for 









these mechanisms before they become pathogenic. Thus, the basis for prenatal treatment 
targeting fetal systemic inflammation has yet to be determined.  
Intrauterine Growth Restriction 
Prenatal Stress & Developmental Programming Mechanisms.  
Fetal growth is contingent upon many factors, including environmental and maternal influences. 
However, alterations to these influences result in changes to the intrauterine environment, 
producing IUGR (Murphy et al., 2006; Scifres and Nelson, 2009). Poor intrauterine conditions in 
late gestation induce fetal survival mechanisms and adaptations that result in IUGR (Murphy et 
al., 2006). Individuals born IUGR are at an increased risk for perinatal morbidity and mortality. 
The largely muscle-centric adaptations that induce metabolic dysfunction result from chronic 
maternal stress that is almost always associated with placental insufficiency (PI-IUGR) 
(Limesand et al., 2007).  IUGR-born individuals are predisposed to an increased risk of poor 
thermoregulation, hypoglycemia, cardiac dysfunction, and infection (Limesand et al., 2007; 
Gaccioli and Lager, 2016). However, consequences are not limited to the fetal stage as fetal 
programming mechanisms yield lifelong greater risk of metabolic and cardiovascular disorders 
and growth deficits (Barker et al., 2006).  
Maternal Causes of IUGR. Although etiologies of placental insufficiency in human and livestock 
pregnancies are still being studied, previous literature indicates the impact of known risk factors 
such as pre-eclampsia, hypertensive disorders, maternal drug use, decreased interpregnancy 
intervals nutritional intake, and environmental stressors (Hendrix and Berghella, 2008; Limesand 
et al., 2018; Yates et al., 2018; Wardinger and Ambati, 2021). The result of these maternal 









vascularity, oxygen permeability, and transporters required for fatty acid and glucose transport to 
the fetus (Thorn et al., 2011; Limesand et al., 2018). Reduced maternal blood flow to the fetus 
and umbilical-placental vascular resistance further compound the functional deficits of the 
placenta and worsen hypoperfusion of glucose and fatty acid in particular (Wardinger and 
Ambati, 2021). A summary of the hallmark fetal pathologies created in late gestation by 
placental insufficiency is presented in Table 1-1.  
Placental Insufficiency Induces IUGR. As the facilitator of nutrient and waste exchange between 
the dam and the fetus, the placenta is a crucial regulator of fetal growth and, specifically, the 
ability for the fetus to meet its growth potential (Murphy et al., 2006). The placenta is a 
metabolically-active tissue that utilizes nutrients and oxygen for its own independent growth as 
well as providing these substrates to the fetus by simple diffusion and transporter-mediated 
transfer (Barry et al., 2008). However, when these processes are impeded by placental stunting 
due to maternal stress, both placental growth and the maternofetal interface are compromised. In 
animal models, placental insufficiency is characterized by as much as 50% decreased total 
placental mass (Brown et al., 2015), as well as reductions in placental villous number, diameter, 
surface area, and degree of branching (Barry et al., 2008). In addition, impaired synthesis of 
Nitric Oxide and polyamines is observed in the stunted placenta (Wu et al., 2006). In a study by 
Limesand et al. (2007), IUGR placentas collected near term in sheep weighed 61% less than 
control placentas (P < 0.01). During peak fetal growth in late gestation, delivery of 
carbohydrates, amino acids, and oxygen by the placenta must meet metabolic demand for rapid 
fetal growth. However, when placental stunting occurs, the stunted placenta cannot deliver 
sufficient oxygen and nutrients to the developing fetus. Thus, the fetus is compromised by a 









2007; Brown et al., 2015; Pendleton et al., 2021). The deprivation of these nutrients due to 
placental insufficiency ultimately lead the fetus to respond with nutrient-sparing programming 
that includes insulin resistance, impaired growth, and altered metabolic processes (Dunlop et al., 
2015).  
Physiological Responses of the Fetus to Placental Insufficiency. The fetal response to 
intrauterine stress is necessary for prenatal survival but also ultimately creates postnatal 
consequences for these individuals. The fetal stress response is characterized by increased 
secretion of catecholamines, pro-inflammatory cytokines, hypoxia, hypoglycemia, and 
hyperlactatemia (Yates et al., 2014; Cadaret et al., 2019c). As an innate survival mechanism, 
nutrient-sparing mechanisms are enacted to provide the essential organs with necessary 
substrates (Limesand et al., 2007). However, these developmental mechanisms reduce growth 
potential as the fetus adapts to being deprived of nutrients for less essential mechanisms such as 
myogenesis (Yates et al., 2018). Because skeletal muscle is a crucial regulator of glucose 
homeostasis, impaired development impacts metabolic health. More direct adaptive 
programming mechanisms in muscle include changes in metabolic processes that limit capacity 
for oxidative metabolism and increased lactate production (Brown et al., 2015; Cadaret et al., 
2019c).  
Nutrient Repartitioning at the Expense of Skeletal Muscle. A key fetal adaptation is redistribution 
of cardiac output towards the body’s most vital organs such as the brain and adrenal glands 
(Dunlop et al., 2015). This acute survival mechanism allows these organs to maintain adequate 
growth and development but at the expense of other tissues and organs such as the heart, 
kidneys, and skeletal muscle. Near term and after birth, the consequences are made apparent by 









approximately 40% of the fetal body mass, skeletal muscle is responsible for 85% of fetal 
insulin-stimulated glucose metabolism (Brown, 2014; Hicks and Yates, 2021). Thus, 
compromised skeletal muscle growth and metabolism is the primary cause for glucose metabolic 
deficits in the IUGR fetus. The metabolic shift that inherently yields such biometric deficits are 
characterized by decreased mitochondrial metabolic capacity which couples oxygen 
consumption with substrate utilization (Pendleton et al., 2021). Although this mechanism is a 
barrier for muscle growth and development, it increases lactate production as a mechanism for 
providing carbon substrates for hepatic glucose production, which helps maintain glucose for 
brain development (Brown et al., 2015). 
Because these adaptations are programmed, metabolic impairment and growth deficits persist 
after parturition even though oxygen and nutrient supply is no longer limited. Individuals 
maintain this thrifty phenotype, and increased fat deposition ultimately results. This further 
compromises intracellular regulation of insulin secretion and responsiveness, resulting in 
dysregulation of blood glucose concentrations and insulin resistance in muscle and adipose tissue 
(Limesand et al., 2007; Gibbs et al., 2020). 
Fetal Programming Mechanisms. Metabolic adaptations that limit the oxidative capacity of 
skeletal muscle occur at the molecular level (Pendleton et al., 2021). These changes can include 
increased PDK1. This in turn inhibits PDH activity and its conversion of pyruvate to acetyl coA, 
which is the entry point for glucose into the TCA cycle that feeds into the electron transport 
chain. This helps explain the suppression of glucose oxidation even when glucose uptake is not 
impaired (Brown et al., 2015). Furthermore, a 4-fold increase in PDK4 expression in IUGR fetal 
skeletal muscle observed by Brown et al. (Brown et al., 2015) was likewise associated with a 10-









underlying limited capacity for glucose oxidation. The combination of normal glucose uptake by 
reduced entry into the TCA cycle means that skeletal muscle lactate production is increased, as 
illustrated by Figure 1-1. Despite concurrent insulin insensitivity, this typically equates to a 
lesser fraction of glucose being oxidized under both basal and insulin-stimulated conditions 
(Limesand et al., 2007; Brown et al., 2015). Work by our lab demonstrates the persistence of 
impaired muscle glucose oxidation at the neonatal and juvenile stages, despite the stress being 
alleviated by birth (Limesand et al., 2007; Gibbs et al., 2020).  
The Health Impact of IUGR Pathologies. 
The maternal etiology of IUGR can be variable, with many different environmental, nutritional, 
or lifestyle conditions leading to the multifaceted reduced functional capacity of the placenta. 
The fetal and postnatal outcomes that result, however, are more consistent and hallmarks of 
impaired metabolic function in IUGR offspring include hypertension, obesity, diabetes, and 
increased risk of cardiovascular diseases (Dunlop et al., 2015). The same molecular pathologies 
occur when pregnant livestock face chronic stress, and thus IUGR-born animals also exhibit poor 
growth and metabolic inefficiency. Therefore, IUGR is a relevant issue that must be addressed in 
both humans and livestock. 
Relevance of IUGR in Humans. Although several common causes of maternal stressors have 
been linked to IUGR in human pregnancies, nearly 50% of IUGR cases occur as the result of an 
unidentified cause (Al-Azemi et al., 2017). IUGR adaptations can effect metabolic function even 
when growth restriction is mild and does not qualify clinically as small for gestational age (SGA) 
birthweight, which means that it and can be misdiagnosed when only bodyweight is measured 









nourished infants with a smaller and shorter frame in the 10th percentile whereas IUGR is 
associated with asymmetric body metrics and ultrasound-diagnosed uteroplacental deficiencies 
(Cyrkowicz and Czekański, 1998; Boehmer et al., 2017). In other words, SGA can occur 
independent of IUGR and conversely, IUGR does not always fit the clinical parameters for SGA. 
Nevertheless, IUGR is reported to afflict up to 53 million infants globally each year (Sedgh et 
al., 2014). Because of challenges associated with global healthcare, only 4-8% of cases are 
diagnostically linked to placental insufficiency (Boehmer et al., 2017). Fleiss et al. (2019) 
estimated that the rate of IUGR in human populations without confounding conditions to be up 
to 9%. However, the rate is exacerbated in lower-resource populations to as high as 30% (Fleiss 
et al., 2019). In addition to greater perinatal morbidity and mortality, these individuals are at 18-
fold greater risk for metabolic disorders that reduce the length and quality of life, including Type 
2 diabetes, obesity, hypertension, and hyperlipidemia (Gatford et al., 2010; Yates et al., 2018; 
Hicks and Yates, 2021).  
Relevance of IUGR in Livestock. IUGR is also a relevant issue in livestock production where low 
birthweight due to IUGR occurs in approximately 10% of all livestock but can effect entire herds 
during harsh environmental or nutritional conditions (Wu et al., 2006). This contributes to an 
estimated annual loss of $12.1 billion in revenue (USDA, 2017) for producers due to a 
combination of poor growth performance, carcass merit discounts, and death loss (Smith et al., 
1995; Boleman et al., 1998; Posont and Yates, 2019). Although most low-birthweight offspring 
survive the perinatal stage, decreased vigor and health further reduce the economic feasibility of 
having these individuals in the herd. As the animal ages, decreased muscle growth coupled with 
increased visceral fat compromise carcass value at the slaughterhouse due to less yield and 









underlying mechanisms and the issue has long been recognized by the industry, IUGR continues 
to cost the livestock producers 8% of their annual product, which is equal to the loss of 3 million 
beef calves, 930,000 dairy calves, and 530,000 lambs each year (Wu et al., 2006; Yates et al., 
2018).  
Sheep as a Model for IUGR. With the need to understand and treat IUGR in both humans and 
animals, ovine models have become popular tools to study fetal and placental growth restriction. 
Using the pregnant sheep as a physiological model is ideal for a multitude of reasons, including 
similar developmental milestones as humans and cattle, tolerance for surgical and experimental 
manipulation during gestation, and the translation of IUGR outcomes that are highly comparable 
to humans and cattle (Regnault, 2003; Beede et al., 2019). The induction of IUGR in the sheep 
model can be accomplished using several methods, including chronic maternal hyperthermia, 
overnutrition of the dam at a young age, chronic maternofetal inflammation, nutrient restriction, 
and surgical placental reduction (Beede et al., 2019). The frequent use of these models in current 
studies show that sheep are an effective model for biomedical and agricultural research aimed at 
assessing fetal programming mechanisms. 
Inflammatory Pathologies in IUGR 
As a part of the stress response to placental insufficiency, IUGR fetuses present physiological 
indicators of systemic inflammation, including changes in white blood cell (WBC) populations 
and increased inflammatory cytokines which play a vital role in metabolic programming. These 
indicators are summarized in Table 1-2. Tumor necrosis factor α (TNFα) and Interleukin-6 (IL-
6) are major inflammatory cytokines that are secreted from leukocytes during nutritional or 









signals (Renshaw et al., 2010). In a study by Al-Azemi et al. (2012), the increased relevance of 
inflammation in the PI-IUGR fetus in comparison to IUGR fetuses produced from other methods 
was abundant as increased IL-2 and IL-12 suggested a propensity towards Th1 expression and 
subsequent TNFα secretion in the PI-IUGR fetus. Moreover, decreased IL-4 and increased IL-10 
concentrations in non-PI IUGR fetuses further supported the correlation between inflammation 
and placental insufficiency (Al-Azemi et al., 2017).  
Stress-induced cytokine Production. Although most commonly associated with immune 
responses, cytokines and other inflammatory factors are parts of the general stress response and 
metabolic regulation. Cytokines are produced in large quantities by macrophages located in 
circulation and peripheral tissues. These proteins can be secreted locally or systemically and are 
elevated in the IUGR fetus (Irani et al., 2009; Cadaret et al., 2019c). The secretion of T helper 1 
(Th1) and T helper 2 (Th2) cells regulate these mechanisms by their individual roles in the 
immune response (Al-Azemi et al., 2017). Th1 cells are responsible for the secretion of 
inflammatory cytokines such as TNFα and IL-2, which activate macrophages in cell-mediated 
immunologic responses, whereas Th2 cells secrete anti-inflammatory cytokines such as IL-4, IL-
5, and IL-10 (Al-Azemi et al., 2017). 
In adult animals, presence of oxidative stress is indicated by alterations in WBC profiles in 
circulation, including increases in leukocytes, granulocytes, lymphocytes, and monocytes as well 
as of inflammatory cytokines (Barnes et al., 2019; Swanson et al., 2020). Romero et al. (1998) 
cited the strong correlation of elevated cytokine concentrations in fetal blood and amniotic fluid 
and acknowledged that both of these were indicators of pre-term labor. However, maternal IL-6 









fetus imposed stress induced adaptations, and these conditions were not correlated with pre-term 
labor.  
Impaired Skeletal Muscle Growth. Fetal hyperplasia determines postnatal muscle fiber number 
and thus is crucial in establishing muscle growth potential. In livestock, this can have a major 
impact on meat yield and quality (Hegarty and Allen, 1978; Greenwood et al., 2000). Adaptive 
changes in IUGR muscle impair myogenesis by disrupting cellular signaling for proliferation and 
differentiation of muscle stem cells called myoblasts (Yates et al., 2014; Posont and Yates, 
2019). These cause long term impacts for total muscle mass and growth potential as the animal 
ages (Bell, 2006). Although acute stimulation by cytokines promotes growth and development of 
skeletal muscle, prolonged exposure is one mechanism whereby proliferation and differentiation 
of myoblasts are restricted in the IUGR fetus (Posont and Yates, 2019). Because myoblast 
function is a rate-limiting process for muscle growth, the functional impairment by persistent 
exposure to cytokines in utero can be considered a key mechanism for decreased hypertrophic 
growth capacity (Cadaret et al., 2019b).  
Inflammatory Effects on Glucose Metabolism & Insulin Secretion. Activation of the Nuclear 
Factor κ-B (NFκB) pathway by TNFα and other cytokines contributes to the shift toward 
muscle-centric glucose metabolism by inhibiting insulin-stimulated Akt phosphorylation and 
subsequent decreased translocation of GLUT-4 transporters for glucose uptake (Lorenzo et al., 
2008; Cadaret et al., 2017). This directly and indirectly helps explain deficient glucose oxidation 
capacity in IUGR skeletal muscle (Cadaret et al., 2019a; Posont et al., 2021b).  
Pancreatic islet cells are also affected by inflammation as proper IL-6 exposure promotes 









to systemic inflammation is detrimental to islet size, density, and pancreatic mass (Boehmer et 
al., 2017). These anatomical deficits in islets lead to alterations in function, as IUGR fetuses 
exhibit altered gene expression for PDX1 and other regulatory factors, thus contributing to 
defects in β-cell replication and decreased insulin content (Limesand et al., 2007; Green et al., 
2010; Boehmer et al., 2017).  
ω-3 Polyunsaturated Fatty Acids as Anti-Inflammitants 
In pregnant women, common additives to prenatal vitamins include eicosapentaenoic acid (EPA) 
and docasohexanoic acid (DHA), as studies support the benefits of the ω-3 polyunsaturated fatty 
acids (ω-3 PUFAs) in fetal neurodevelopment, immune system development, and central 
nervous system health (Greenberg et al., 2008; Best et al., 2016). Although these ω-3 PUFAs can 
be synthesized from ⍺-linoleic acid (ALA) in the adult, the developing fetus does not have this 
ability and thus the only derivatives come from placental transfer as excess after satisfying the 
metabolic needs of the mother (Larque et al., 2012). Studies have established the capacity for ω-
3 PUFAs to mitigate inflammatory pathways and also promote the production and secretion of 
anti-inflammatory cytokines (Chen et al., 2017; Inoue et al., 2017; Gonzalez-Soto and Mutch, 
2021). Epidemiological studies in the past have associated the consumption of long-chain ω-3 
PUFAs with decreased risk of inflammatory syndromes such as arthritis and pulmonary vascular 
resistance (Sharma et al., 2017). The designation between ω-3 PUFAs, which are anti-
inflammatory, and ω-6 PUFAs, which can increase inflammatory tone, is determined by whether 
a double bond is located at the 3rd or 6th carbon from the terminal methyl group, respectively 
(Kim et al., 2019). As illustrated in Figure 1-2, EPA is a carboxylic acid chain that is 20 carbons 
in length and contains five double bonds, the 1st of which is located at the 3rd carbon (designating 









1st of which is located at the 6th carbon from the terminal methyl. Both EPA and DHA are 
synthesized from the essential fatty acid, ALA, although the process is energetically costly 
(Burdge and Calder, 2005). This stepwise process has several intermediate steps but begins with 
the desaturation of ALA to stearidonic acid by delta-6-desaturase. It is this 1st step that is rate 
limiting, however. Next, elongase converts stearidonic acid into eicosatetraenoic acid and finally 
to EPA by delta-5-de-saturase (Lenihan-Geels and Bishop, 2016). ALA is highly abundant in 
common foods such as flaxseed, soybean, and canola whereas EPA and DHA can be obtained 
directly from fish, seaweed, and algae without having to be synthesized by the body. In order to 
be metabolized for energy, these PUFAs enter the cellular matrix as an acyl-carnitine by way of 
a carnitine transporter before phosphorylation back to a fatty acid, which can then undergo β-
oxidation (Burdge and Calder, 2005). As a nutraceutical, EPA induced a 25% decrease in 
pulmonary vascular resistance in fetal lambs, whereas DHA had no effect (Sharma et al., 2017). 
Literature provides comprehensive evidence that ω-3 PUFA inhibit many aspects of 
inflammation including decreased cytokine and eicosanoid production (Caughey et al., 1996; 
Velten et al., 2014; Allam-Ndoul et al., 2016). Moreover, the expression of transcription factors 
inhibits the activity of the NFκB pathway (Allam-Ndoul et al., 2016). Therefore, the capacity for 
ω-3 PUFA to mitigate inflammatory pathologies is established.  
During late gestation, fatty acids are required for brain and adipose tissue development but may 
only be acquired from the maternal diet via placental transfer (Murphy et al., 2006). This 
transport can occur in several ways, including the use of fatty acid transport proteins (FATP)-1, 
2, 3, 4, 5, 6 and fatty acid binding protein (FABP) -1, 3, 4, 5, 7 (Devarshi et al., 2019). As 









these FATP is also upregulated, and subsequent increase of these PUFA in cord blood are 
observed, along with the FABP required for their placental transfer (Greenberg et al., 2008).  
The cumulative alterations in white blood cells and cytokine profiles are hallmarks of systemic 
inflammation and likewise, hallmarks of IUGR. Thus, ω-3 PUFA provide promise to mitigate 
inflammatory signaling its programmed deficits in the IUGR fetus. As transporter mechanisms 
are upregulated during gestation, we know that these nutraceuticals have the ability to be 
transported across the placenta and therefore provide promise in future treatment through 
maternal ingestion (Connor et al., 1996; Greenberg et al., 2008).  
Conclusion 
Work by our lab and others continue to characterize the mechanistic deficits of underlying IUGR 
that contribute to lifelong metabolic and biometric deficits in humans and livestock. Although 
these mechanisms are beginning to be identified, little is known regarding how they may be 
mediated in utero. The objectives of the following studies were aimed at establishing a basis for 
how fetal systemic inflammation may be alleviated by nutraceutical intervention during late 
gestation. Specifically, the effectiveness of direct fetal infusion of ω-3 PUFA on IUGR fetal 
growth and metabolic outcomes was evaluated by measuring fetal biometrics, β-cell function, 
skeletal muscle glucose uptake, and skeletal muscle oxidative metabolism in a well-characterized 





























Figure 1-2. Biochemical Structures of ⍺-linoleic acid (ALA), eicosapentaenoic acid (EPA), and 

























Physiological Parameter Conditions in the IUGR Fetus 
O2 
~60% ↓ arterial blood oxygen (Brown et al., 2015); ~50% ↓ 
fetal oxygen (Macko et al., 2016) 
Lactate 4-fold ↑ lactate concentrations (Brown et al., 2015); 
Insulin 
~55% ↓ insulin concentrations (Brown et al., 2015);  
~69% ↓ insulin concentrations (Limesand et al., 2007);  
~56% ↓ β-cell mass (Leos et al., 2010) 
Glucose 
~50% ↓ glucose concentrations (Limesand et al., 2007); 
~ 30% ↓ glucose concentrations (Brown et al., 2015); 
~50% ↓ glucose oxidation rate (Limesand et al., 2007); 
Catecholamines 
7-fold ↑ Norepinephrine (Yates et al., 2016); 5-fold ↑ 
Epinephrine (Limesand et al., 2007) 
IGF-1 
~ 80% ↓ circulating fetal IGF-1 (Thorne et al., 2009); ~ 33% 
↓ fetal arterial IGF-1 (Macko et al., 2016); 
PDK4-1  4-fold ↑ PDK4 expression (Brown et al., 2015) 
Myoblast Function 
~13% ↓ proliferated and 
~46% ↓ differentiated myoblasts (Yates et al., 2014); ~12% ↓ 
myoblast proliferation (Riley et al., 2016);  ~50% ↓ cross-
























Decreased skeletal muscle glucose metabolism and impaired β cell function in IUGR fetal 
sheep were improved by daily ω-3 PUFA infusions. 
The findings presented in this chapter were published in the 2021 proceedings of the American 
Society of Animal Science, Western Section, which is peer-reviewed.  
Lacey, T. A., R. L. Gibbs, M. S. Most, H. N. Beer, Z. M. Hicks, P. C. Grijalva, J. L. Petersen, 
and D. T. Yates. 2021. Decreased fetal biometrics and impaired β cell function in IUGR fetal 
sheep are improved by daily ω-3 PUFA infusion. Transl. Anim. Sci. 5(Suppl 1) doi: 
10.1093/tas/txab168 
ABSTRACT 
Poor intrauterine conditions created by placental insufficiency result in intrauterine 
growth restriction (IUGR) of the fetus. Decreased fetal nutrients and O2 coincide with fetal 
inflammation, which appears to have a role in thrifty programming mechanisms, including 
reduced skeletal muscle glucose oxidative metabolism. Thus, our objective was to target 
inflammation in IUGR fetal sheep by infusing an anti-inflammatory ω-3 polyunsaturated fatty 
acid (PUFA), eicosapentaenoic acid (EPA), to improve homeostatic blood parameters and 
metabolic outcomes. In this study, IUGR fetuses were produced by maternal hyperthermia-
induced placental insufficiency. Surgical placement of indwelling fetal femoral catheters allowed 
arterial blood collection and daily intravenous infusion of IUGR fetuses with saline (i.e., IUGR; 
n=5) or eicosapentaenoic acid (i.e., IUGR+EPA; n=6) for 5 ± 1 days beginning at 119 ± 1 days 
of gestational age (dGA). Controls (n=12) were saline-infused fetuses from thermoneutral ewes. 









blood parameters were assessed by arterial blood collection for CBC, blood gases, and 
metabolites. Glucose-stimulated insulin secretion was assessed at 122 ± 1 dGA and hindlimb-
specific glucose metabolism was determined at 123 ± 1 dGA. Daily circulating white blood cells 
(WBC) were elevated (P < 0.05) in IUGR compared to control and IUGR+EPA fetuses. In 
addition, platelets were elevated (P < 0.05) in IUGR and IUGR+EPA fetuses compared to 
controls. Blood lactate and pCO2 were increased (P < 0.05) in IUGR fetuses compared to 
controls however did not differ from IUGR+EPA fetuses. Basal plasma insulin was less (P < 
0.05) for IUGR but not for IUGR+EPA fetuses compared to controls. Glucose-stimulated insulin 
secretion was less (P < 0.05) for IUGR and IUGR+EPA fetuses compared to controls but was 
greater (P < 0.05) for IUGR+EPA than for IUGR fetuses. Blood pO2, pCO2, HCO3, Na+, K+, and 
Cl- were less (P < 0.05) for IUGR fetuses than controls but were greater (P < 0.05) for 
IUGR+EPA than for IUGR fetuses. BUN and NEFA concentrations were increased (P < 0.05) 
for IUGR but not IUGR+EPA fetuses compared to controls. HDLC did not differ between 
controls and IUGR fetuses but was increased (P < 0.05) in IUGR+EPA fetuses. Hindlimb 
glucose uptake rates were decreased (P < 0.05) for IUGR and IUGR+EPA fetuses and hindlimb 
insulin-stimulated glucose oxidation was decreased (P < 0.05) for IUGR and IUGR+EPA 
fetuses, compared to controls. These findings demonstrate that infusion of the anti-inflammatory 











Placental insufficiency-induced intrauterine growth restriction (IUGR) results in muscle-
centric fetal programming that impairs glucose metabolism (Yates et al., 2019) and yields 
asymmetric growth that favors fat deposition (Gibbs et al., 2020). Decreased nutrients and O2 
impose fetal stress, initiating fetal adaptations for survival that also increase the risk for 
hypertension, obesity, and Type 2 diabetes after birth (Yates et al., 2011). Chronic exposure of 
skeletal muscle and pancreatic islets to inflammatory cytokines appears to be a key culprit for the 
programming mechanisms that yield IUGR and in turn life-long metabolic dysfunction (Yates et 
al., 2018; Posont et al., 2021b). Thus, the objective of this study was to evaluate the effects of 
manipulating stress-induced inflammatory activity in the IUGR fetus. Previous studies have 
reported that ω-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory actions and also 
stimulate glucose metabolism (Kim et al., 2019). If administration of ω-3 PUFA can effectively 
improve glucose metabolism and insulin sensitivity, then glucose homeostasis, metabolic 
efficiency, and growth in the IUGR fetus may be recovered. We hypothesized that manipulation 
of inflammatory pathways in the skeletal muscle of IUGR fetuses via daily infusion with 
eicosapentaenoic acid (EPA) in late gestation would improve fetal blood indicators of metabolic 
health, glucose homeostasis, biometric growth, and body composition. 
MATERIALS & METHODS 
Animals and Experimental Design 
All studies were approved by the Institutional Animal Care and Use Committee at the 
University of Nebraska-Lincoln, which is AAALAC International-accredited. Time-mated 
Polypay ewes were used to produce control and placental insufficiency-induced IUGR fetuses as 









40°C and 35% relative humidity from the 40th to the 95th day of gestational age (dGA) before 
returning to thermoneutral conditions (25°C) for the duration of the study. Ewes carrying control 
fetuses were pair-fed to the average daily intake of the ewes carrying IUGR fetuses. At 118 dGA, 
partial cesarean surgeries were performed to place indwelling catheters in the femoral vein and 
artery of the fetus and an arterial blood flow probe as previously described (Cadaret et al., 
2019c). On dGA 119 ± 1, IUGR fetuses were randomly assigned to receive daily 1-hour i.v. 
infusions of 0.25 mg/d EPA (i.e., IUGR+EPA; n=6) or ethanol-spiked (EtOH) saline placebo 
(ie. IUGR; n=5) for 5 ± 1 d. EPA concentrate was suspended in EtOH (Sigma-Aldrich). Control 
fetuses (n=12) also received daily EtOH-spiked saline infusions. 
Fetal arterial blood samples were collected daily from 120 to 125 dGA. Complete blood 
cell counts (CBC) were determined using a HemaTrue Veterinary Chemistry Analyzer (Heska, 
Loveland, CO). An ABL90 FLEX blood gas analyzer (Radiometer America, Bera, CA) was used 
to measure blood gases and metabolites.  
In Vivo Fetal Metabolism 
Glucose-Stimulated Insulin Secretion. Pancreatic β cell function was assessed using a 
square-wave hyperglycemic clamp at 122 ± 1 dGA as previously described (Cadaret et al., 
2019c). Three arterial samples were taken in 5-minute intervals at baseline (i.e., resting) levels 
then a 3 mL bolus of 33% dextrose solution was administered intravenously (i.v.) followed by a 
continuous variable-rate infusion in order to achieve steady-state hyperglycemia (i.e., 2.5X 
baseline). After steady-state was achieved and at least twenty minutes after the bolus, three 
additional arterial samples were taken at 5-minute intervals at hyperglycemia. Blood samples 
collected in heparinized syringes were analyzed to measure blood gases and metabolites via 









and plasma was collected and stored at -80°C. Plasma insulin concentrations were then 
determined in duplicate using the Bovine Insulin ELISA (Alpco, Salem, NH), which has been 
validated for sheep. Plasma NEFA concentrations were calculated via commercial NEFA 
colorimetric assay (Sigma-Aldrich). Plasma BUN, and HDLc concentrations were measured by 
Vitros 250 Chemistry Analyzer (Biomedical and Obesity Research Core, Lincoln, NE). Inter- 
and intra- assay coefficients of variance were below 10%.  
In Vivo Hindlimb Glucose Metabolism. Hindlimb-specific glucose metabolism was 
estimated by a hyperinsulinemic-euglycemic clamp (HEC) at 123 ± 1 dGA as previously 
described (Yates et al., 2019). For this study, fetuses were administered a radiolabeled glucose 
tracer (18.75μCi/ml, U-[14C]-glucose; Perkin-Elmer, Waltham, MA) infused at a constant rate of 
1 mL/hour following a 1 mL i.v. bolus. Four pairs of simultaneous femoral arterial and venous 
samples were then collected at 5-minute intervals to establish a baseline before bolusing 1 mL of 
33% dextrose (150 mg/kg, i.v.) and 2mL of insulin (250 mU/kg; Humulin-R, Eli Lilly, 
Indianapolis, IN). A variable-rate infusion of 33% dextrose was used to maintain euglycemia. 
Insulin was infused at a constant rate of 0.5 ml/kg/hour until steady state HEC was achieved 
(±10% baseline glucose). Four more pairs of simultaneous arterial and venous samples were then 
taken at 5-minute intervals. Samples were analyzed for blood gases and metabolites via ABL90 
and plasma was isolated and collected to be stored at -80°C until insulin concentrations were 
determined via Bovine Insulin ELISA.  
Additional arterial and venous samples (0.33 mL, respectively) were deposited in 0.5 mL 
micro-centrifuge tubes containing 2M HCl and fixed inside 20 mL scintillation vials containing 
1M NaOH to estimate hindlimb glucose oxidation rates as previously described (Posont et al., 









oxidative metabolism is estimated by the amount of 14CO2 released from the blood by HCl and 
recaptured by the NaOH at the bottom of the scintillation vial. Micro-centrifuge tubes were then 
manually removed, and scintillation vials were filled with UltimaGold scintillation fluid (Perkin-
Elmer). A liquid scintillation counter (Beckman-Counter 1900 TA, Brea, CA) was then used to 
quantify radiolabeled 14CO2. Glucose oxidation by the hindlimb tissues was then calculated using 
the difference in 14CO2 between arterial and venous samples at each given time of sample 
collection. The response of the hindlimb tissues to insulin stimulation was determined by 
calculating the fold-change in glucose oxidation between basal and HEC periods. Glucose uptake 
was estimated by the difference in arterial and venous glucose concentrations. Technical 
replicates at baseline and HEC levels were averaged.  
Statistical Analysis   
All data were analyzed with SAS 9.4 (SAS Institute, Cary, NC) using the mixed 
procedure specific for repeated measures with the fetus as the experimental unit. Repeated 
measures of blood parameters in the GSIS, HEC, and daily blood samples were analyzed for 
effects due to treatment, time (dGA or period), and the interaction. Variables for time were 
treated as repeated measures. Sex was treated as a random effect. Technical replicates were 
averaged, and data are presented as mean ± standard error. Significant differences were declared 
at α ≤ 0.05 and tendencies at α ≤ 0.10.  
RESULTS 
Daily Hematology 
No group x dGA interactions were observed for any hematological measures. Total white 









controls and IUGR+EPA fetuses, regardless of dGA (Figure 2-1). Circulating lymphocytes were 
greater (P < 0.05) in IUGR and IUGR+EPA and monocytes tended to be greater (P = 0.06) in 
IUGR and IUGR+EPA fetuses compared to controls. Granulocytes, hematocrit (Hct), mean 
corpuscular volume (MCV), hemoglobin concentrations (Hb), mean platelet volume (MPV), red 
blood cells (RBC), and red blood cell width distribution (RWD) did not differ among 
experimental groups. Hemoglobin concentrations were less (P < 0.05) in IUGR and IUGR+EPA 
fetuses than controls (Figure 2-1). Platelet concentrations were greater (P < 0.05) in IUGR 
fetuses compared to controls and were greater (P < 0.05) in IUGR+EPA fetuses than in IUGR 
and control fetuses.  
Daily Blood Gases and Metabolites 
No group x dGA interactions were observed for blood glucose, lactate, pH, partial 
pressure CO2 (pCO2), or partial pressure O2 (pO2). Daily blood glucose concentrations were less 
(P < 0.05) in IUGR fetuses than controls regardless of day and was intermediate (P < 0.05) for 
IUGR+EPA fetuses between controls and IUGR fetuses (Figure 2-3). Lactate concentrations 
were greater (P < 0.05) in IUGR and IUGR+EPA fetuses compared to controls. Blood pH did 
not differ among experimental groups. Blood pCO2 was greater (P < 0.05) and pO2 was less (P < 
0.05) in IUGR and IUGR+EPA fetuses compared to controls. A group x dGA interaction (P < 
0.05) was observed for daily blood HCO3 concentrations, which were greater (P < 0.05) in IUGR 
and IUGR+EPA fetuses on dGA 122, 123, and 124. HCO3 was also greater (P < 0.05) in 
IUGR+EPA than controls at dGA 120.  
Glucose-Stimulated Insulin Secretion  
Experimental group x glycemic period interactions were observed (P<0.05) for plasma 









(P<0.05) for IUGR fetuses than for controls and IUGR+EPA, regardless of period. Glucose was 
also increased (P<0.05) during hyperglycemia compared to baseline for all groups (Figure 2-4). 
Plasma insulin was less (P < 0.05) for IUGR fetuses than for controls and IUGR+EPA fetuses at 
baseline. At hyperglycemia, plasma insulin was less (P < 0.05) in IUGR fetuses compared to 
controls and was intermediate (P < 0.05) for IUGR+EPA between controls and IUGR fetuses. 
Glucose-to-insulin ratios were less (P<0.05) for IUGR fetuses than for controls and IUGR+EPA 
fetuses at baseline. At hyperglycemia, glucose-to-insulin ratios were less (P < 0.05) for IUGR 
fetuses than controls and were intermediate (P < 0.05) for IUGR+EPA fetuses between controls 
and IUGR fetuses. Blood lactate did not differ among treatment groups, regardless of period but 
was greater (P<0.05) during hyperglycemia than baseline in all groups.  
No group x period interactions were observed for blood pO2, pCO2, pH, hemoglobin, 
hematocrit, hemoglobin bound O2 (O2HB), hemoglobin bound CO (COHB) or HCO3. Blood pO2 
was less (P < 0.05) for IUGR fetuses than controls and was intermediate (P < 0.05) for 
IUGR+EPA fetuses between IUGR fetuses and controls, regardless of period (Figure 2-5). 
Blood pCO2 was greater (P < 0.05) for IUGR fetuses but not IUGR+EPA fetuses than for 
controls and was greater (P < 0.05) during hyperglycemia than baseline regardless of 
experimental group. Blood pH was less (P < 0.05) for IUGR fetuses and was intermediate (P < 
0.05) for IUGR+EPA fetuses between IUGR fetuses and controls. It was also decreased (P < 
0.05) during hyperglycemia compared to baseline regardless of experimental group. Blood 
hemoglobin and hematocrit did not differ among experimental groups, regardless of period. 
Blood O2HB was less (P < 0.05) in IUGR fetuses but did not differ between controls and 
IUGR+EPA fetuses. It was also decreased (P < 0.05) during hyperglycemia in all experimental 









differ from IUGR+EPA fetuses, regardless of period. Blood HCO3 was greater (P < 0.05) for 
IUGR fetuses but less (P<0.05) for IUGR+EPA fetuses compared to controls, regardless of 
period. 
No group x period interactions were observed for Na+, K+, Cl-, or Ca2+ concentrations. 
Blood Na+ was greater (P < 0.05) for IUGR fetuses but not IUGR+EPA fetuses than for controls, 
regardless of period. Blood K+ was greater (P < 0.05) in IUGR fetuses and was intermediate (P < 
0.05) for IUGR+EPA between controls and IUGR fetuses (Figure 2-6). Blood K+ decreased 
during hyperglycemia, regardless of experimental group. Blood Cl- was greater (P < 0.05) for 
IUGR fetuses than controls and IUGR+EPA fetuses, regardless of period. Blood Ca2+ did not 
differ among experimental groups regardless of period. 
No group x period interactions were observed for non-esterified fatty acids (NEFA), 
blood plasma urea nitrogen (BUN), and high-density lipoprotein cholesterol (HDLc). Total 
blood NEFA concentrations were greater (P < 0.05) in IUGR fetuses compared to controls and 
IUGR+EPA fetuses (Figure 2-7). Blood NEFA were also decreased (P < 0.05) during 
hyperglycemia compared to baseline in all groups. BUN were greater (P < 0.05) in IUGR fetuses 
than controls, and were intermediate (P < 0.05) for IUGR+EPA fetuses between controls and 
IUGR fetuses. HDLc did not differ between IUGR fetuses and controls but were greater (P < 
0.05) in IUGR+EPA fetuses, regardless of period.  
Hindlimb Glucose Metabolism 
 A group x insulinemic period interaction was observed (P < 0.05) for blood K+ but not for 
any other blood parameters. Blood glucose was less (P < 0.05) in IUGR fetuses compared to 
controls and was intermediate (P < 0.05) for IUGR+EPA fetuses between IUGR fetuses and 









than for controls. Blood pH was greater (P < 0.05) in IUGR fetuses than controls and 
IUGR+EPA fetuses (Figure 2-9). Blood pCO2 did not differ among experimental groups but 
blood pO2 was tended to be less (P < 0.10) in IUGR and IUGR+EPA compared to controls. 
There was no difference among experimental groups for hemoglobin or hematocrit 
concentrations (Figure-10). Blood plasma NEFA concentrations were greater (P < 0.05) in 
IUGR fetuses and was intermediate (P < 0.05) for IUGR+EPA fetuses and controls. HCO3 was 
less (P < 0.05) in IUGR fetuses than controls and IUGR+EPA fetuses.  
Blood Na+ was greater (P < 0.05) in IUGR fetuses compared to controls and further 
increased (P < 0.05) in IUGR+EPA fetuses compared to IUGR fetuses, regardless of insulinemic 
period (Figure 2-11). A group x period interaction was observed (P < 0.05) for K+ which were 
greater (P < 0.05) in IUGR fetuses than controls and intermediate for IUGR+EPA fetuses in the 
baseline period. During HEC, blood K+ was greater (P < 0.05) in IUGR fetuses compared to 
controls and less (P < 0.05) in IUGR+EPA fetuses compared to controls. Blood Cl- was greater 
(P < 0.05) in IUGR fetuses than controls and greater (P < 0.05) in IUGR+EPA fetuses compared 
to IUGR fetuses and controls, regardless of period. Blood Ca2+ was not different among 
experimental groups but was increased (P < 0.05) during HEC.  
Hindlimb glucose uptake rates were less (P < 0.05) for IUGR fetuses and IUGR+EPA 
fetuses than controls (Figure-12). Similarly, hindlimb insulin-stimulated glucose oxidation was 
less (P < 0.05) in IUGR and IUGR+EPA fetuses compared to controls.  
DISCUSSION 
 In this study, we found that some but not all deficits caused by IUGR were mitigated by 
daily infusion of fetuses with the anti-inflammatory ω-3 PUFA, EPA. The presence of systemic 









of WBC, lymphocyte, and monocytes were increased in the IUGR fetuses and total WBC 
concentrations were recovered by 5-day EPA infusion to IUGR fetuses. Previous studies by our 
lab (Barnes et al., 2019; Swanson et al., 2020) have demonstrated in adult animals that the 
presence of increased leukocytes, granulocytes, lymphocytes, and monocytes are associated with 
chronic heat stress even in the absence of direct immune challenges. The chronic heat stress used 
in these studies produced many of the same physiological deficits as IUGR and demonstrates a 
correlation between changes in immune profile and blood indicators of inflammation, such as 
oxidative cellular stress and the secretion of inflammatory cytokines. In particular, the increase 
in lymphocytes and monocytes in the IUGR fetuses of the present study support our hypothesis 
that systemic inflammation occurs in IUGR fetuses. However, although the elevation of total 
WBC was decreased by EPA infusions, lymphocytes and monocytes remained elevated in EPA-
infused IUGR fetuses, suggesting that full mediation of the mechanisms stimulating immune cell 
changes was not achieved. Surprisingly, platelet concentrations were increased only marginally 
in saline-infused IUGR fetuses but were 122% greater than normal in EPA-infused IUGR 
fetuses. We know from previous studies that increased circulating platelets are typically 
associated with classical immune insults to the body (Koupenova et al., 2018), which was 
perhaps an indirect component of this IUGR fetal model. Moreover, the further exacerbation by 
ω-3 PUFA infusion was unexpected based on previous literature. In studies by Dyerberg and 
Bang (1979) and Yamada et al. (1998), blood platelets were decreased in humans and rats 
receiving ω-3 PUFA supplementation, respectively. It is unclear why our results differed, but we 
would suspect there are other confounding mechanisms at work that may be responsible for these 









Daily blood glucose concentrations show that IUGR fetuses were moderately 
hypoglycemic, which was an expected outcome of placental insufficiency. However, blood 
glucose was partially recovered by daily EPA infusions. In contrast, blood lactate was increased 
in IUGR fetuses and EPA-infused IUGR fetuses alike, suggesting that administration of EPA had 
little effect on tissue glycolysis rates. Although we did not measure antioxidant status in our 
fetuses, it is possible that increased oxidative stress and the associated stimulation of 
inflammatory cytokine secretion (i.e., increase in inflammatory tone) impaired metabolic 
function earlier and more profoundly than our late-term intervention could overcome (Renshaw 
et al., 2010). Comparable impairments in blood pO2 and pCO2 between IUGR fetuses infused 
with saline and those infused with EPA further support this possibility. Interestingly, 
improvements in blood HCO3 due to EPA-infusion appeared to take time as HCO3 was increased 
in IUGR fetuses and were not improved by EPA until the final day of the 5-day infusion period. 
Circulating HCO3 plays a pivotal buffering role to protect against oxidative stress, and thus 
increased HCO3 concentrations in our IUGR fetuses is likely a compensatory buffering response 
that is ultimately made less necessary by daily ω-3 PUFA infusions.  
Basal and glucose-stimulated insulin secretion, which were impaired by over 40% in our 
IUGR fetuses, were each improved by 5-day ω-3 PUFA infusion. This indicates that deficits in 
IUGR β cell function are at least in part due to enhanced inflammatory tone and thus benefit 
from inflammatory mitigation. Despite complete recovery of basal insulin secretion, only partial 
recovery of insulin secretion occurred under hyperglycemic conditions, indicating that there are 
clearly factors other than inflammation also contribute to poor glucose-stimulus-secretion 
coupling in the IUGR β cells. Although full islet morphology assessments were not performed, 









mass reduced by placental insufficiency directly leads to poor insulin secretion (Gatford and 
Simmons, 2013). Moreover, fetal β cells require glucose for proper development, and EPA has 
been shown to improve glucose uptake in other cell types (Figueras et al., 2011). Similar 
improvements in β cells would help explain the better functionality observed here. In addition, 
glucose-to-insulin ratios were recovered in IUGR fetuses receiving ω-3 PUFA treatment at 
baseline and were partially recovered at hyperglycemia, and the hypoglycemia observed in 
IUGR fetuses was also fully recovered. These results build upon our earlier studies that 
demonstrated fetal inflammation in the IUGR fetus (Cadaret et al., 2019a; Posont and Yates, 
2019) by showing that metabolic function in IUGR fetuses could be improved when fetal 
inflammation is controlled. 
Although previous studies suggested a shift to greater relative glycolytic lactate 
production concomitant with a reduction in glucose the oxidation in the IUGR concentrations, 
blood lactate concentrations did not differ among any of our groups under basal or 
hyperglycemic conditions. However, this may have been due to a coincident increase in hepatic 
lactate uptake, which would be consistent with increased Cori Cycle activity in the IUGR fetus 
(Thorne et al., 2014). Nevertheless, increased lactate production can cause insulin resistance in 
IUGR individuals (Kim et al., 2019), and previous work by us and others shows that limited 
capacity for glucose oxidation in favor of lactate production provides carbon substrates for 
hepatic glucose production in the IUGR fetus (Brown et al., 2015; Cadaret et al., 2019a). As 
expected, blood pH was decreased in our IUGR fetuses, despite our observation of greater blood 
HCO3. Unlike HCO3, however, blood pH was partially recovered by EPA infusion. Controlling 
fetal inflammation with ω-3 PUFA also improved CO2 and O2, which were predictably increased 









study whether these improvements were due to change in placental function or fetal metabolism, 
and thus follow-up studies are warranted. Together, these findings further support our hypothesis 
that skeletal muscle glucose metabolism in IUGR fetuses reflects a key nutrient-sparing 
mechanism.  
In addition to the adaptive change in glucose metabolism, lipid homeostasis and protein 
cycling may also be altered in the IUGR fetus. NEFA concentrations are indicative of increased 
lipolytic activity and are consistent with increased fat mobilization and/or decreased fat 
deposition, which is a hallmark of IUGR (Ortega-Senovilla et al., 2010; Yates et al., 2018). In 
our present study, IUGR fetuses exhibited increased blood NEFA concentrations that were 
completely resolved in EPA-infused IUGR fetuses, demonstrating a beneficial effect of these 
long-chain fatty acids in lipid homeostasis. Moreover, BUN levels were increased in IUGR 
fetuses but were lower in EPA-infused IUGR fetuses than IUGR fetuses and controls. We 
postulate that this was indicative of less protein catabolism, although we cannot rule out the 
possibility of increased kidney function. Indeed, decreased renal blood flow has been observed 
previously in IUGR fetuses and suggested disturbance of renal function (Todros et al., 1999). 
Thus, increased BUN in the blood of IUGR fetuses could have been due at least in part to a lack 
of filtration of residual urea, causing it to accumulate in the bloodstream. Interestingly, HDLc 
was not affected by IUGR alone, but was increased by EPA infusions. Considering the function 
of HDLc molecules, we presume that there were being taken from peripheral tissue back to the 
liver at greater rates. This occurs for the attached cholesterol to be utilized as precursor for bile 
salts, after which and is the HDL is esterified and returned to the liver (Gupta and Rajagopal, 
2007). Because of this, it would be reasonable to expect the increase in circulating PUFA due to 









Hyperinsulinemic Euglycemic Clamp 
 Similar to our results during daily and hyperglycemic clamp assessments, blood glucose 
was diminished by approximately 64% in IUGR fetuses during the basal and hyperinsulinemic 
periods of the HEC study. However, these concentrations were partially rescued by infusion of 
EPA. Conversely, blood lactate concentrations were increased in IUGR fetuses and were not 
improved by EPA infusions. Together with other stress factors, the impact of lactate levels on 
insulin resistance in IUGR tissues could be a contributor to and/or cause of the change in glucose 
metabolism (Kim et al., 2019). Regardless, lactate production provides substrates for hepatic 
glucose production in the IUGR fetus via the Cori Cycle, since glucose itself cannot leave 
skeletal muscle (Brown et al., 2015; Cadaret et al., 2019a).These results allow us to postulate 
that, although glycemia was partially recovered, the lack of differences for blood lactate 
concentrations may be explained by increased hepatic lactate utilization that offsets the presumed 
increase in secretion of lactate by muscle. This, more direct studies of lactate production rates are 
needed. In contrast to lactate, blood pH was increased in IUGR fetuses, but was recovered by 
daily EPA infusion. This would indicate that more mechanisms than just lactate were influencing 
blood pH. For example, although pCO2, which was recovered in the daily blood samples as well 
as during the hyperglycemic clamp did not differ among groups during the HEC study, which 
might help explain the paradoxical rise in pH which had previously been less in out IUGR 
fetuses.  
 Poor skeletal muscle glucose uptake is a well-characterized hallmark of IUGR fetuses 
and offspring (Cadaret et al., 2019c; Yates et al., 2019; Posont et al., 2021b). Thus, it was not 
surprising that in the present study, hindlimb glucose uptake was reduced by 400% in the IUGR 









no improvement. This suggests that EPA was not successful in recovering glucose uptake despite 
our other evidence that inflammation was the underlying mechanism for this deficit. This 
contrasted previous findings in the literature, specifically when evaluating the effect of the ω-3 
PUFA, EPA, on GLUT4 translocation, which is the rate-limiting step for insulin-stimulated 
glucose uptake (Kim et al., 2019). However, preserved glucose uptake in IUGR fetuses has been 
observed previously (Limesand et al., 2007; Brown et al., 2015) and it is worth noting that only 
about 40% of the hindlimb tissues are skeletal muscle (Hicks and Yates, 2021). Nevertheless, the 
response of skeletal muscle glucose oxidation rates to insulin was markedly impaired in the 
IUGR fetuses, and this deficit was not improved by EPA-infusion. Indeed, the 8-fold change in 
glucose oxidation observed when uncompromised fetuses were infused with insulin only 
increased 3-fold in IUGR fetuses, whether infused with saline or EPA. This suggests that 
although several components of glucose homeostasis were improved by daily EPA infusion into 
IUGR fetuses, insulin-mediated metabolic processes in the hindlimb tissues were not.  
Together, these findings allow us to conclude that multiple factors contributing to the 
dynamic dysregulation of glucose homeostasis in the late-term IUGR fetus were improved by 
controlling fetal systemic inflammation through EPA infusion. Improvements in insulin secretion 
indicated that pancreatic β cell function was recovered. However, other important indicators of 
metabolic function and health remained deficient. This provides direction to the next step in 
order to determine what additional programming mechanisms must be targeted for a broader 
improvement in metabolism. Nevertheless, results of the current study indicate that moderation 
of fetal inflammation via EPA supplementation can have a beneficial impact on developmental 













Figure 2-1. Daily total white blood cell (A), lymphocyte (B), monocyte (C), and granulocyte (D) 
concentrations from Control (n=12), IUGR (n=5), and IUGR+EPA (n=6) fetuses. a,b means with 











Figure 2-2. Data are shown for daily hematocrit percentage (A), hemoglobin (B), mean corpuscular 
volume (C), red blood cell width distribution (D), red blood cells (E) and platelet count (D) from Control 











Figure 2-3. Daily blood glucose (A), pH (B), partial pressure O2 (C), blood lactate (D), HCO3 (E) and 
partial pressure CO2 (D) from Control (n=12), IUGR (n=5), and IUGR+EPA (n=6) fetuses. a,b means 











Figure 2-4. Blood glucose (A), glucose-to-insulin ratio (B), plasma insulin (C), and blood lactate (D) 
concentrations determined at basal and hyperglycemic conditions. Data are shown for Control (n=12), 











Figure 2-5. Data are shown for pH (A), partial pressure O2 (B), partial pressure CO2 (C), HCO3 (D), 
hemoglobin (E), and hematocrit % (D) at basal and hyperglycemic conditions. Data are shown for Control 











Figure 2-6. Na+ (A), K+ (B), Cl- (C), and Ca2+ (D) measures are reported at basal and hyperglycemic 











Figure 2-7. Data are shown for plasma blood urea nitrogen (A), plasma HDLC (B), and plasma NEFA 
concentrations (C) for Control (n=12), IUGR (n=3), and IUGR+EPA (n=4) fetuses. a,b means with 











Figure 2-8. Blood glucose at arterial (A), venous (B), arteriovenous difference (C). Blood lactate at 
arterial (D), venous (E), and the arteriovenous difference (F). Data are shown at basal and HEC 











Figure 2-9. Blood pH (A), HCO3 (B), partial pressure O2 (C), and partial pressure CO2 (D) at basal and 











Figure 2-10. Data are shown for hemoglobin (A), hematocrit % (B), and plasma NEFA (C) are shown at 
basal and HEC for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses. a,b means with differing 











Figure 2-11. Basal and HEC concentrations for Na+ (A), K+ (B), Cl- (C), and Ca2+ (D) are shown for 











Figure 2-12. Insulin sensitivity for hindlimb skeletal muscle glucose oxidation during steady-state 
hyperinsulinemia measured by fold change from basal and hyper insulinemic-euglycemic conditions. 
Data are shown for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses. a,b means with differing 











Fetal growth, body composition, and ex vivo glucose metabolism are impaired in the IUGR 
fetal sheep but are improved by daily ω-3 PUFA infusion. 
 
ABSTRACT 
Chronic maternal stress during peak placental development yields placental 
insufficiency-induced intrauterine growth restriction (IUGR) and causes biometric and 
metabolic deficits in the late-term fetus and offspring. Placental insufficiency limits nutrient 
transfer across the placenta, which forces the fetus to adapt its physiological processes for 
growth and metabolism in order to survive. These adaptations repartition limited nutrients to 
vital tissues and organs, and thus less vital tissues such as skeletal muscle are compromised by 
decreased growth potential and impaired metabolic capacity. In this study, IUGR fetal sheep 
were produced using the maternal hyperthermia model while controls were housed at 
thermoneutral conditions. Indwelling fetal femoral catheters were placed at 118 days of gestation 
(dGA) to allow for daily intravenous (i.v.) infusion of IUGR fetuses with eicosapentaenoic acid 
(EPA) (IUGR+EPA; n=6) or EtOH-spiked (EtOH) saline placebo (IUGR; n=5) and controls 
with an EtOH-saline placebo (n=12). Infusions were administered for 5 ±1 d beginning at 120 ±1 
dGA. Necropsy was performed at 126 ±1 dGA and fetal biometrics were assessed. IUGR fetuses 
were lighter (P < 0.05) than controls but IUGR+EPA bodyweight was partially recovered. IUGR 
fetuses also exhibited reduced (P < 0.05) hindlimb, semitendinosus (ST), and longissimus dorsi 
(LD) masses and tended to exhibit reduced (P < 0.10) soleus mass compared to controls. EPA 









soleus and ST mass compared to saline-infused IUGR fetuses. Flexor digitorum superficialis 
(FDS) muscle mass did not differ among groups. IUGR reduced (P < 0.05) heart, lung, and 
kidney mass and tended to reduce (P < 0.10) liver mass. EPA infusion recovered (P < 0.05) lung 
and kidney mass and tended to recover (P < 0.10) liver mass but did not improve heart mass. 
Brain mass did not differ among groups. Fiber type proportions in the ST were estimated by 
myosin heavy chain ratios determined by electrophoresis. Myosin for Type I fibers did not differ 
among groups, but myosin for Type IIA fibers tended to be decreased (P < 0.10) and myosin for 
Type IIx fibers tended to be increased (P < 0.10) in IUGR fetuses compared to controls. EPA 
infusion tended (P < 0.10) to recover myosin ratios for two of these fiber types. ST glycogen 
content was not different among groups. Ex vivo analysis of skeletal muscle specific glucose 
metabolism indicated a decrease (P < 0.05) in glucose uptake for IUGR fetal muscle that was 
partially recovered (P < 0.05) by EPA infusion. Likewise, glucose oxidation rates were impaired 
(P < 0.05) for IUGR fetal muscle but were fully recovered by EPA infusions. From these 
findings, we can conclude that daily administration of ω-3 PUFA directly to the fetus was 












Acute stress is beneficial for a multitude of reasons, including its activation of growth 
factor synthesis and physiological alterations as part of the fight or flight response (Weissman, 
1990). However, prolonged stress exposure in pregnant animals is detrimental to the life-long 
health of offspring (Hales and Barker, 1992). Placental insufficiency-induced intrauterine growth 
restriction (IUGR) occurs as a result of chronic maternal stress during peak placental 
development, which causes stunting of the placenta by re-routing uterine blood flow (Murphy et 
al., 2006; Brown et al., 2015). Placental stunting results in a limited supply of nutrients to the 
fetus and therefore prompts fetal stress responses that induce nutrient-sparing adaptive 
mechanisms (Limesand et al., 2007; Brown et al., 2015; Dunlop et al., 2015). Although these 
adaptations ensure intrauterine survival, they lead to programmed deficits such as impaired 
myogenesis, asymmetric growth, and dysregulation of glucose metabolism that persist after birth 
(Yates et al., 2014; Cadaret et al., 2019c; Gibbs et al., 2020). Such adaptive mechanisms appear 
to occur in part as a response to systemic inflammation and remain even when the systemic 
inflammation is alleviated after birth. Therefore, the objective of this study was to evaluate the 
effectiveness of daily ω-3 polyunsaturated fatty acids (PUFA) infusions on fetal IUGR sheep in 
order to mediate inflammation. Previous literature has established the effectiveness of ω-3 PUFA 
in decreasing inflammatory signaling (Caughey et al., 1996; Velten et al., 2014; Allam-Ndoul et 
al., 2016; Kim et al., 2019). Thus, use of this nutraceutical in mediating the fetal inflammatory 
response may improve metabolism and biometric deficits. We hypothesized that these deficits 
will be improved by daily infusion of IUGR fetuses with the ω-3 PUFA, eicosapentaenoic acid 










MATERIALS & METHODS 
Animals and Experimental Design 
These studies were approved by the Institutional Animal Care and Use Committee at the 
University of Nebraska-Lincoln, an AAALAC International-accredited institution. The well-
characterized maternal hyperthermia model was used to generate placental insufficiency induced 
IUGR fetal sheep as previously described by Yates et al. (2016) and Cadaret et al. (2018). 
Briefly, gestating ewes were exposed to elevated ambient conditions of 40°C and 35% relative 
humidity during peak placental development (dGA 40-95) before returning to thermoneutral 
conditions (25°C) alongside their control counterparts. This study utilized time-mated Polypay 
ewes to carry control and IUGR fetuses. Indwelling catheters were placed at 118 dGA in the 
femoral vein and artery of the fetus as previously described (Cadaret et al., 2019a). 
Catheterizations allowed for the daily infusion of fetuses.  IUGR fetuses were randomly assigned 
to receive daily infusions of 0.25 mg/d EPA (i.e., IUGR+EPA; n=6) or saline placebo (i.e., 
IUGR; n=5) from dGA 121 to 125 ± 1 d. Control fetuses (n=12) also received a saline infusion. 
Infusions were administered intravenously (i.v.) into the fetal femoral vein over a period of 1 
hour. Animals were euthanized at dGA 125 ± 1 d by double barbiturate overdose and tissue and 
organ metrics were assessed. Fetal bodyweight and total hindlimb mass were recorded in 
addition to masses for semitendinosus (ST), soleus, longissimus dorsi (LD), and flexor digitorum 
superficialis (FDS) muscles. Organ metrics included heart, lung, liver, kidney, and brain masses.  
Ex Vivo Glucose Metabolism  
 Flexor digitorum superficialis (FDS) and soleus muscles were collected at necropsy for 









saline solution (PBS), and strips were split from tendon-to-tendon, creating at 50 ± 5 mg strips. 
Strips were pre-incubated for 1 hour in Krebs-Heneslit Buffer (KHB) spiked with no additive 
(basal), or insulin (5 mU/ml Humulin-R). Muscle strips were then washed in respectively-spiked 
glucose-free KHB media for 20 min. Glucose oxidation was measured using sealed dual-well 
chambers as previously described (Cadaret et al., 2017). Briefly, muscle strips were incubated in 
KHB spiked with 5 mM [14C-U] D-glucose for 2 hr. The adjacent well contained 1M NaOH. 
Chambers were then cooled on ice and wells containing muscle strips were injected with 2M 
HCl and allowed to incubate at 4°C for an additional 1 hr. During this final incubation, 
bicarbonate-bound 14CO2 was liberated from the media and captured by the NaOH. The 
forementioned NaOH was collected and deposited in a 20-mL scintillation vial and filled with 
with UltimaGold scintillation fluid (Perkin-Elmer). Vials were assessed with an LC counter 
(Beckman-Counter 1900 TA, Brea, CA) to measure 14CO2 concentrations. To measure glucose 
uptake, muscle strips were incubated in KHB media containing no additive (basal) or insulin (5 
mU/ml Humulin-R) and 1 mM [3H] 2-deoxy-d-glucose for 20 min. Following incubation, muscle 
strips were cooled and washed in PBS, and placed in 20-mL scintillation vials with 2M NaOH to 
be lysed at 37°C for 2 hours. Liquid scintillation was then used to determine the concentration of 
[3H] 2-deoxy-d-glucose for each lysate.  
Myosin Heavy Chain Electrophoresis 
At necropsy, 100 mg of snap-frozen ST muscle was collected, homogenized, and sonified 
in 400 μl of RIPA buffer (Thermo Fisher). Samples were then centrifuged (14,000 x g, 2min, 
4°C) and supernatant was collected. Pierce BCA Assay (Thermo Fisher) was used to measure 
total protein content. Samples were then combined with   Bio-Rad 4× Laemmli Sample Buffer 









to room temperature and 40 μg of protein was loaded into each well. Upper running buffer 
contained 100 mM Tris, 150 mM glycine, 0.1% SDS, and 0.07% 2β-mercaptoethanol in distilled 
water, and the lower running buffer consisted of 50 mM Tris, 75 mM glycine, and 0.05% SDS in 
distilled water. Mini-PROTEAN gradient gels (4-15%; Bio-RAD). Electrophoresis was 
performed at room temperature on a PowerPac Basic (Bio-RAD) at a constant voltage of 110V 
for 3 hours. Following electrophoresis, gels were stained overnight in Gel-Code Blue (Thermo 
Fischer) at room temperature, washed in distilled water, and imaged using an Odyssey infrared 
imaging system (LI-COR Biosciences, Lincoln, NE). Quantification of MyHC-I, MyHC-IIA, 
and MyHC-IIx was completed by densitometry (Image Studio Lite Ver 5.0; LI-COR) in order to 
estimate fiber type ratios.  
Glycogen Colorimetric Assay  
Snap-frozen ST muscle samples (100 mg) were homogenized with 1 mL distilled water 
and sonicated. Homogenates were boiled (95°C x 5 minutes), centrifuged (13,000g x 5 minutes), 
and supernatant was collected. Samples were diluted in Hydrolysis buffer (Sigma-Aldrich) at 
1:200. Glycogen content was then measured by a commercial Glycogen Assay Kit (Sigma-
Aldrich, St. Louis, MO). Inter- and intra- assay coefficients of variance were less than 15%.  
Statistical Analysis   
All data were analyzed with SAS 9.4 (SAS Institute, Cary, NC) using the mixed 
procedure, with the fetus as the experimental unit. Sex was treated as a random effect. Technical 
replicates were averaged, and data are presented as mean ± standard error. Significant 












At necropsy, fetal body weight was 23% less (P < 0.05) for IUGR fetuses than for 
controls and was intermediate (P < 0.05) for IUGR+EPA fetuses (Table 3-1). Fetal hindlimbs 
were lighter (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls. ST 
muscle mass was less (P < 0.05), and soleus muscle mass tended to be less (P < 0.10) for IUGR 
fetuses than controls and were intermediate (P < 0.05) for IUGR+EPA fetuses. LD muscle mass 
was less (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls. FDS 
muscle mass did not differ among groups. Heart mass was less (P < 0.05) and liver mass tended 
to be less (P < 0.05) for IUGR and IUGR+EPA fetuses than for controls. Lung mass and kidney 
mass were lighter (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls. 
Brain mass did not differ among experimental groups.  
Ex vivo Skeletal Muscle Glucose Metabolism 
Glucose uptake rates in FDS and soleus muscle were 36% less (P < 0.05) for IUGR fetal 
muscle than controls but were only 14% less (P < 0.05) for IUGR+EPA fetal muscle, regardless 
of media conditions (Figure 3-1). Glucose oxidation likewise was less (P < 0.05) for IUGR fetal 
muscle compared to controls, but fully recovered in IUGR+EPA fetal muscle compared to 
controls, regardless of media conditions. Glucose oxidation was increased (P < 0.05) when 
muscle was incubated in insulin-spiked media compared to basal media, regardless of 
experimental group.  
Skeletal Muscle Composition 
Proportions of MyHC-I in ST protein isolates did not differ among groups. However, 









compared to IUGR+EPA fetuses and controls (Figure 3-2).. Semitendinosus glycogen content 
did not differ among groups.   
 
DISCUSSION 
In this study, we found that biometric deficits in the IUGR fetus were consistent with the 
decreased muscle mass and asymmetric growth as previously observed (Cadaret et al., 2019c; 
Yates et al., 2019; Posont et al., 2021b). However, targeting systemic inflammation in these 
fetuses provided promising results that indicate improvement in total body and muscle-specific 
growth. As expected, bodyweight was less in IUGR fetuses because of restricted growth in utero. 
Moreover, partial recovery of several growth and body symmetry metrics indicates that EPA 
administration is effective on potential intervention for biometric deficits. In fact, the mass of the 
hindlimb, two of the three hindlimb muscles (ST and soleus) and the LD, were fully recovered 
by this daily ω-3 PUFA regimen of EPA. The importance of skeletal muscle to metabolic health 
and glucose homeostasis cannot be overstated, as it clears 65% of total glucose from circulation 
(Yates et al., 2018). Thus, improved muscle mass almost assuredly contributed to improved 
glucose-to-insulin ratios reported in the previous chapter. Improved muscle mass presumably 
increased the capacity for glucose utilization and oxidation independent of any changes in 
metabolic function proper. Consistent with known nutrient repartitioning mechanisms, our IUGR 
fetuses developed smaller hearts, lungs, livers, and kidneys (Brown et al., 2015; Dunlop et al., 
2015). Daily ω-3 PUFA administration of EPA was successful in recovering lung and kidney 
size but did not improve heart or liver mass. The later observations were somewhat unexpected, 
as both heart and liver appeared to be priority tissues for preserved growth in earlier studies 









three groups indicates that growth of the fetus’ highest priority, neural tissue, was indeed 
maintained.  
Deficits in skeletal muscle-specific glucose metabolism observed in IUGR fetuses was 
improved by ω-3 PUFA in our ex vivo analysis. Inflammation in the IUGR fetuses presumably 
decreased translocation of GLUT-4 transporters which is the rate-limiting mechanism for 
insulin-stimulated glucose uptake (Lorenzo et al., 2008). Although this study did not directly 
assess GLUT-4, the results of decreased glucose uptake was observed in muscle from IUGR 
fetuses. Kim et al. (2019) provided a description of the mechanism by which EPA increases 
AMP:ATP ratios, thus increasing phosphorylation of AMP-activated protein kinase (AMPK). 
This AMPK activation step is important in the general regulation of cellular growth and 
metabolism but acts in part by increasing translocation of GLUT-4 in muscle. Whether by this or 
other mechanisms, our study found a partial recovery of glucose uptake when IUGR fetuses were 
infused with EPA, suggesting that inflammatory mediation was at least partially inhibiting 
inflammatory action and, in turn, reducing glucose uptake. In addition to glucose uptake, we 
observed reduced glucose oxidation rates in muscle from IUGR fetuses. This was expected based 
on the findings of previous studies that reported reduced whole-body glucose oxidation in IUGR 
fetal sheep (Limesand et al., 2007; Brown et al., 2015). Brown et al. (2015) described this as 
being the result of a shift in metabolism to greater lactate production concurrent with a reduced 
conversion of pyruvate to acetyl coA. Ultimately, this resulted in downstream changes that 
decreased the capacity for glucose oxidation, regardless of insulin stimulation. In our study, 
glucose oxidation was reduced by 28% in the IUGR fetal muscles but was recovered in both 
basal and insulin-spiked media when the muscle strips were from IUGR fetuses that had received 









Decreased Type I and IIA muscle fibers in IUGR fetuses are correlated with insulin 
insensitivity and altered glycolytic enzyme activity (Jensen et al., 2007). As such a shift in 
relative numbers from Type I and IIA fibers, which are oxidative in nature, to Type IIx fibers, 
which are glycolytic, would have obvious detrimental effects on glucose oxidation (Yates et al., 
2016). Although myosin heavy chain indicators assessed in this study indicated that Type I fibers 
were not decreased in numbers by IUGR, decreased number of Type IIA fibers and increased 
numbers of Type IIx fibers was consistent with reduced glucose oxidation found in this study. 
Moreover, although ω-3 PUFA infusion unexpectedly failed to improve glucose oxidation in 
vivo, the combined findings of improved Type IIA fiber ratios and improved ex vivo glucose 
oxidation, indicate that ω-3 PUFA infusion was indeed beneficial for muscle glucose 
metabolism. Furthermore, the recovery of glucose oxidation ex vivo was independent of insulin 
activity. This likely explains the lack of an effect in vivo, as hindlimb glucose oxidation was 
assessed as the responsiveness to insulin stimulation.  
 
IMPLICATIONS 
The growth and metabolic deficits imposed by IUGR have been widely established in literature. 
These deficits, which result from physiological adaptations made in utero, yield prenatal and 
postnatal consequences for offspring. Nutraceutical moderation of inflammatory signaling in 
these fetuses, however, appeared to pose a promising intervention strategy to improve the 
pathological outcomes of these programming deficits. This study demonstrates that ω-3 PUFA 
was dynamically effective at recovering biometric deficits and partially recovering skeletal 
muscle-specific glucose metabolism. Although a fundamental step in establishing their efficacy, 









further research is warranted to evaluate the effectiveness of administering EPA maternally via 










Figure 3-1. Proportion of myosin heavy chains, Type 1, 2A, and 2X, are shown for Control (n=12), 











Figure 3-2. Ex vivo hindlimb specific glucose metabolism was assessed at necropsy by isolation of FDS 
and soleus muscle. Glucose uptake (A) and oxidation (B) are reported for Control (n=12), IUGR (n=5), 











Table 3-1. Fetal biometrics for ω-3 PUFA-infused IUGR fetal sheep.  
 
Data are presented as mean ± SE. 
 a,b,c means with different superscripts differ (P < 0.05).  
x,y,z means with different superscripts tend to differ (P < 0.10).  
NS, not significant.   
Mass Experimental Group P-Value 
  Control IUGR IUGR+EPA   
Fetal Weight, kg 3.1 ± 0.1a 2.4 ± 0.2b 2.9 ± 0.1c 0.03 
Hindlimb, g 308 ± 13a 238 ± 20 b 294 ± 17 a 0.04 
ST, g 6.5 ± 0.3a 4.5 ± 0.5b 5.5 ± 0.4c 0.03 
Soleus, g 1.03 ± 0.13x 0.63 ± 0.11y 0.89 ± 0.15z 0.09 
LD, g  61 ± 3a 47 ± 2b 60 ± 2a < 0.001 
FDS, g  5.57 ± 0.39 3.83 ± 0.88 5.66 ± 0.45 NS 
Heart, g 27.1 ± 1.3a 21.5 ± 1.4b 24.1 ± 1.4b 0.02 
Lungs, g 101 ± 4a 88 ± 3b 95 ± 4a 0.02 
Liver, g 121 ± 8 x 102 ± 8y 104 ± 7y 0.07 
Kidneys, g 21.8 ± 1a 13.9 ± 1.7b 20.5 ± 1.3a <0.001 












Al-Azemi, M., R. Raghupathy, and F. Azizieh. 2017. Pro-inflammatory and anti-inflammatory 
cytokine profiles in fetal growth restriction. Clin Exp Obstet Gynecol 44(1):98-103.  
Allam-Ndoul, B., F. Guénard, O. Barbier, and M.-C. Vohl. 2016. Effect of n-3 fatty acids on the 
expression of inflammatory genes in THP-1 macrophages. Lipids in Health and Disease 
15(1)doi: 10.1186/s12944-016-0241-4 
Barker, D. J. P., S. P. Bagby, and M. A. Hanson. 2006. Mechanisms of Disease: in utero 
programming in the pathogenesis of hypertension. Nature Clinical Practice Nephrology 
2(12):700-707. doi: 10.1038/ncpneph0344 
Barnes, T. L., C. N. Cadaret, K. A. Beede, T. B. Schmidt, J. L. Petersen, and D. T. Yates. 2019. 
Hypertrophic muscle growth and metabolic efficiency were impaired by chronic heat 
stress, improved by zilpaterol supplementation, and not affected by ractopamine 
supplementation in feedlot lambs1. Journal of Animal Science 97(10):4101-4113. doi: 
10.1093/jas/skz271 
Barry, J. S., P. J. Rozance, and R. V. Anthony. 2008. An Animal Model of Placental 
Insufficiency-Induced Intrauterine Growth Restriction. Seminars in Perinatology 
32(3):225-230. doi: https://doi.org/10.1053/j.semperi.2007.11.004 
Beede, K. A., S. W. Limesand, J. L. Petersen, and D. T. Yates. 2019. Real supermodels wear 
wool: summarizing the impact of the pregnant sheep as an animal model for adaptive 
fetal programming. Animal Frontiers 9(3):34-43.  
Bell, A. 2006. Prenatal programming of postnatal productivity and health of livestock: a brief 
review. Australian Journal of Experimental Agriculture 46(7):725-732.  
Best, K. P., M. Gold, D. Kennedy, J. Martin, and M. Makrides. 2016. Omega-3 long-chain 
PUFA intake during pregnancy and allergic disease outcomes in the offspring: a 
systematic review and meta-analysis of observational studies and randomized controlled 
trials. The American Journal of Clinical Nutrition 103(1):128-143. doi: 
10.3945/ajcn.115.111104 
Boehmer, B. H., S. W. Limesand, and P. J. Rozance. 2017. The impact of IUGR on pancreatic 
islet development and β-cell function. Journal of Endocrinology 235(2):R63-R76.  
Boleman, S., S. Boleman, W. Morgan, D. Hale, D. Griffin, J. Savell, R. Ames, M. Smith, J. 
Tatum, and T. Field. 1998. National Beef Quality Audit-1995: Survey of producer-related 
defects and carcass quality and quantity attributes. Journal of Animal Science 76(1):96-
103.  
Brown, L. D. 2014. Endocrine regulation of fetal skeletal muscle growth: impact on future 
metabolic health. Journal of Endocrinology 221(2):R13-R29. doi: 10.1530/joe-13-0567 
Brown, L. D., P. J. Rozance, J. L. Bruce, J. E. Friedman, W. W. Hay, Jr., and S. R. Wesolowski. 
2015. Limited capacity for glucose oxidation in fetal sheep with intrauterine growth 
restriction. Am J Physiol Regul Integr Comp Physiol 309(8):R920-928. doi: 
10.1152/ajpregu.00197.2015 
Burdge, G. C., and P. C. Calder. 2005. Conversion of α-linolenic acid to longer-chain 
polyunsaturated fatty acids in human adults. Reproduction Nutrition Development 
45(5):581-597. doi: 10.1051/rnd:2005047 
Cadaret, C. N., K. A. Beede, H. E. Riley, and D. T. Yates. 2017. Acute exposure of primary rat 









increases glucose oxidation rates independent of the impact on insulin signaling or 
glucose uptake. Cytokine 96:107-113.  
Cadaret, C. N., E. M. Merrick, T. L. Barnes, K. A. Beede, R. J. Posont, J. L. Petersen, and D. T. 
Yates. 2018. Sustained maternal inflammation during the early third trimester yields fetal 
adaptations that impair subsequent skeletal muscle growth and glucose metabolism in 
sheep1. Translational Animal Science 2(suppl_1):S14-S18. doi: 10.1093/tas/txy047 
Cadaret, C. N., E. M. Merrick, T. L. Barnes, K. A. Beede, R. J. Posont, J. L. Petersen, and D. T. 
Yates. 2019a. Sustained maternal inflammation during the early third-trimester yields 
intrauterine growth restriction, impaired skeletal muscle glucose metabolism, and 
diminished beta-cell function in fetal sheep1,2. J Anim Sci 97(12):4822-4833. doi: 
10.1093/jas/skz321 
Cadaret, C. N., E. M. Merrick, T. L. Barnes, K. A. Beede, R. J. Posont, J. L. Petersen, and D. T. 
Yates. 2019b. Sustained maternal inflammation during the early third-trimester yields 
intrauterine growth restriction, impaired skeletal muscle glucose metabolism, and 
diminished β-cell function in fetal sheep1,2. Journal of Animal Science 97(12):4822-
4833. doi: 10.1093/jas/skz321 
Cadaret, C. N., R. J. Posont, K. A. Beede, H. E. Riley, J. D. Loy, and D. T. Yates. 2019c. 
Maternal inflammation at midgestation impairs subsequent fetal myoblast function and 
skeletal muscle growth in rats, resulting in intrauterine growth restriction at term1. 
Translational Animal Science 3(2):867-876. doi: 10.1093/tas/txz037 
Caughey, G. E., E. Mantzioris, R. A. Gibson, L. G. Cleland, and M. J. James. 1996. The effect 
on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched 
in n-3 fatty acids from vegetable oil or fish oil. The American Journal of Clinical 
Nutrition 63(1):116-122. doi: 10.1093/ajcn/63.1.116 
Chen, X., A. C. Kelly, D. T. Yates, A. R. Macko, R. M. Lynch, and S. W. Limesand. 2017. Islet 
adaptations in fetal sheep persist following chronic exposure to high norepinephrine. 
Journal of Endocrinology 232(2):285-295. doi: 10.1530/joe-16-0445 
Connor, W. E., R. Lowensohn, and L. Hatcher. 1996. Increased docosahexaenoic acid levels in 
human newborn infants by administration of sardines and fish oil during pregnancy. 
Lipids 31(1):S183-S187. doi: 10.1007/bf02637073 
Cyrkowicz, A., and A. Czekański. 1998. Intrauterine growth retardation (IUGR) vs small for 
gestational age fetus (SGA). Diagnostic aspects. Ginekologia polska 69(4):213-217.  
Devarshi, P. P., R. W. Grant, C. J. Ikonte, and S. Hazels Mitmesser. 2019. Maternal Omega-3 
Nutrition, Placental Transfer and Fetal Brain Development in Gestational Diabetes and 
Preeclampsia. Nutrients 11(5)doi: 10.3390/nu11051107 
Dunlop, K., M. Cedrone, J. Staples, and T. Regnault. 2015. Altered Fetal Skeletal Muscle 
Nutrient Metabolism Following an Adverse In Utero Environment and the Modulation of 
Later Life Insulin Sensitivity. Nutrients 7(2):1202-1216. doi: 10.3390/nu7021202 
Dyerberg, J., and H. O. Bang. 1979. HÆMOSTATIC FUNCTION AND PLATELET 
POLYUNSATURATED FATTY ACIDS IN ESKIMOS. The Lancet 314(8140):433-435. 
doi: https://doi.org/10.1016/S0140-6736(79)91490-9 
Everitt, G. C. 1968. In Growth and  Development of Mammals. Proceedings of the Fourteenth 
Easter School in Agricultural Science, University of Nottingham:131.  
Figueras, M., M. Olivan, S. Busquets, F. J. Lopez-Soriano, and J. M. Argiles. 2011. Effects of 









diabetes: improvement of the inflammatory status. Obesity (Silver Spring) 19(2):362-
369. doi: 10.1038/oby.2010.194 
Fleiss, B., F. Wong, F. Brownfoot, I. K. Shearer, O. Baud, D. W. Walker, P. Gressens, and M. 
Tolcos. 2019. Knowledge gaps and emerging research areas in intrauterine growth 
restriction-associated brain injury. Frontiers in endocrinology 10:188.  
Gaccioli, F., and S. Lager. 2016. Placental Nutrient Transport and Intrauterine Growth 
Restriction. Frontiers in Physiology 7(40)(Mini Review) doi: 10.3389/fphys.2016.00040 
Gatford, K. L., and R. A. Simmons. 2013. Prenatal programming of insulin secretion in 
intrauterine growth restriction. Clin Obstet Gynecol 56(3):520-528. doi: 
10.1097/GRF.0b013e31829e5b29 
Gatford, K. L., R. A. Simmons, M. J. De Blasio, J. S. Robinson, and J. A. Owens. 2010. Review: 
Placental Programming of Postnatal Diabetes and Impaired Insulin Action after IUGR. 
Placenta 31:S60-S65. doi: 10.1016/j.placenta.2009.12.015 
Gibbs, R. L., R. M. Swanson, J. K. Beard, T. B. Schmidt, J. L. Petersen, and D. T. Yates. 2020. 
Deficits in growth, muscle mass, and body composition following placental 
insufficiency-induced intrauterine growth restriction persisted in lambs at 60 d of age but 
were improved by daily clenbuterol supplementation. Translational Animal Science 
4(Supplement_1):S53-S57. doi: 10.1093/tas/txaa097 
Godfrey, K. M., and D. J. Barker. 2000. Fetal nutrition and adult disease. The American Journal 
of Clinical Nutrition 71(5):1344S-1352S. doi: 10.1093/ajcn/71.5.1344s 
Gonzalez-Soto, M., and D. M. Mutch. 2021. Diet Regulation of Long-Chain PUFA Synthesis: 
Role of Macronutrients, Micronutrients, and Polyphenols on Δ-5/Δ-6 Desaturases and 
Elongases 2/5. Advances in Nutrition 12(3):980-994.  
Green, A. S., P. J. Rozance, and S. W. Limesand. 2010. Consequences of a compromised 
intrauterine environment on islet function. The Journal of endocrinology 205(3):211.  
Greenberg, J. A., S. J. Bell, and W. Van Ausdal. 2008. Omega-3 fatty acid supplementation 
during pregnancy. Reviews in obstetrics and Gynecology 1(4):162.  
Greenwood, P. L., A. S. Hunt, J. W. Hermanson, and A. W. Bell. 2000. Effects of birth weight 
and postnatal nutrition on neonatal sheep: II. Skeletal muscle growth and development2. 
Journal of Animal Science 78(1):50-61. doi: 10.2527/2000.78150x 
Gupta, S., and G. Rajagopal. 2007. The significance of plasma high density lipoprotein 
cholesterol (hdlc). Nepal Med Coll J, 9(3):212-4. 
Hales, C. N., and D. J. P. Barker. 1992. Type 2 (non-insulin-dependent) diabetes mellitus: the 
thrifty phenotype hypothesis. Diabetologia 35(7):595-601. doi: 10.1007/bf00400248 
Hegarty, P., and C. Allen. 1978. Effect of pre-natal runting on the post-natal development of 
skeletal muscles in swine and rats. Journal of Animal Science 46(6):1634-1640.  
Hendrix, N., and V. Berghella. 2008. Non-Placental Causes of Intrauterine Growth Restriction. 
Seminars in Perinatology 32(3):161-165. doi: 
https://doi.org/10.1053/j.semperi.2008.02.004 
Hicks, Z. M., and D. T. Yates. 2021. Going Up Inflame: Reviewing the Underexplored Role of 
Inflammatory Programming in Stress-Induced Intrauterine Growth Restricted Livestock. 
Frontiers in Animal Science 2(63)(Review) doi: 10.3389/fanim.2021.761421 
Inoue, T., M. Tanaka, S. Masuda, R. Ohue-Kitano, H. Yamakage, K. Muranaka, H. Wada, T. 
Kusakabe, A. Shimatsu, and K. Hasegawa. 2017. Omega-3 polyunsaturated fatty acids 









by activating SIRT1 pathways. Biochimica et Biophysica Acta (BBA)-Molecular and 
Cell Biology of Lipids 1862(5):552-560.  
Irani, R. A., Y. Zhang, S. C. Blackwell, C. C. Zhou, S. M. Ramin, R. E. Kellems, and Y. Xia. 
2009. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine 
growth restriction seen in preeclampsia. Journal of Experimental Medicine 206(12):2809-
2822. doi: 10.1084/jem.20090872 
Jensen, C. B., H. Storgaard, S. Madsbad, E. A. Richter, and A. A. Vaag. 2007. Altered Skeletal 
Muscle Fiber Composition and Size Precede Whole-Body Insulin Resistance in Young 
Men with Low Birth Weight. The Journal of Clinical Endocrinology & Metabolism 
92(4):1530-1534. doi: 10.1210/jc.2006-2360 
Kim, N., M. S. Kang, M. Nam, S. A. Kim, G. S. Hwang, and H. S. Kim. 2019. Eicosapentaenoic 
Acid (EPA) Modulates Glucose Metabolism by Targeting AMP-Activated Protein Kinase 
(AMPK) Pathway. Int J Mol Sci 20(19)doi: 10.3390/ijms20194751 
Koupenova, M., L. Clancy, H. A. Corkrey, and J. E. Freedman. 2018. Circulating Platelets as 
Mediators of Immunity, Inflammation, and Thrombosis. Circulation Research 
122(2):337-351. doi: 10.1161/circresaha.117.310795 
Larque, E., A. Gil-Sanchez, M. T. Prieto-Sanchez, and B. Koletzko. 2012. Omega 3 fatty acids, 
gestation and pregnancy outcomes. Br J Nutr 107 Suppl 2:S77-84. doi: 
10.1017/S0007114512001481 
Lenihan-Geels, G., and K. S. Bishop. 2016. Alternative Origins for Omega-3 Fatty Acids in the 
Diet, Omega-3 Fatty Acids. p. 475-486. 
Limesand, S. W., L. E. Camacho, A. C. Kelly, and A. T. Antolic. 2018. Impact of thermal stress 
on placental function and fetal physiology. Animal Reproduction 15(Suppl. 1):886-898. 
doi: 10.21451/1984-3143-ar2018-0056 
Limesand, S. W., P. J. Rozance, D. Smith, and W. W. Hay, Jr. 2007. Increased insulin sensitivity 
and maintenance of glucose utilization rates in fetal sheep with placental insufficiency 
and intrauterine growth restriction. Am J Physiol Endocrinol Metab 293(6):E1716-1725. 
doi: 10.1152/ajpendo.00459.2007 
Lorenzo, M., S. Fernandez-Veledo, R. Vila-Bedmar, L. Garcia-Guerra, C. De Alvaro, and I. 
Nieto-Vazquez. 2008. Insulin resistance induced by tumor necrosis factor-alpha in 
myocytes and brown adipocytes. J Anim Sci 86(14 Suppl):E94-104. doi: 
10.2527/jas.2007-0462 
Murphy, V. E., R. Smith, W. B. Giles, and V. L. Clifton. 2006. Endocrine regulation of human 
fetal growth: the role of the mother, placenta, and fetus. Endocr Rev 27(2):141-169. doi: 
10.1210/er.2005-0011 
Ortega-Senovilla, H., G. Alvino, E. Taricco, I. Cetin, and E. Herrera. 2010. Enhanced circulating 
retinol and non-esterified fatty acids in pregnancies complicated with intrauterine growth 
restriction. Clinical Science 118(5):351-358. doi: 10.1042/cs20090292 
Pendleton, A. L., S. R. Wesolowski, T. R. H. Regnault, R. M. Lynch, and S. W. Limesand. 2021. 
Dimming the Powerhouse: Mitochondrial Dysfunction in the Liver and Skeletal Muscle 
of Intrauterine Growth Restricted Fetuses. Frontiers in Endocrinology 12doi: 
10.3389/fendo.2021.612888 
Posont, R. J., C. N. Cadaret, J. K. Beard, R. M. Swanson, R. L. Gibbs, E. S. Marks-Nelson, J. L. 
Petersen, and D. T. Yates. 2021a. Maternofetal inflammation induced for 2 wk in late 
gestation reduced birth weight and impaired neonatal growth and skeletal muscle glucose 









Posont, R. J., C. N. Cadaret, J. K. Beard, R. M. Swanson, R. L. Gibbs, E. S. Marks-Nelson, J. L. 
Petersen, and D. T. Yates. 2021b. Maternofetal inflammation induced for two weeks in 
late gestation reduced birthweight and impaired neonatal growth and skeletal muscle 
glucose metabolism in lambs. J Anim Sci doi: 10.1093/jas/skab102 
Posont, R. J., and D. T. Yates. 2019. Postnatal Nutrient Repartitioning due to Adaptive 
Developmental Programming. Vet Clin North Am Food Anim Pract 35(2):277-288. doi: 
10.1016/j.cvfa.2019.02.001 
Raghupathy, R., M. Al-Azemi, and F. Azizieh. 2012. Intrauterine Growth Restriction: Cytokine 
Profiles of Trophoblast Antigen-Stimulated Maternal Lymphocytes. Clinical and 
Developmental Immunology 2012:1-10. doi: 10.1155/2012/734865 
Regnault, T. 2003. Ruminant models of prenatal growth restriction. Reproduction 61(5689):183-
194.  
Renshaw, G. M. C., G. Wise, and P. R. Dodd. 2010. Ecophysiology of neuronal metabolism in 
transiently oxygen-depleted environments: Evidence that GABA is accumulated pre-
synaptically in the cerebellum. Comparative Biochemistry and Physiology Part A: 
Molecular & Integrative Physiology 155(4):486-492. doi: 10.1016/j.cbpa.2009.10.039 
Romero, R., R. Gomez, F. Ghezzi, B. H. Yoon, M. Mazor, S. S. Edwin, and S. M. Berry. 1998. 
A fetal systemic inflammatory response is followed by the spontaneous onset of preterm 
parturition. American Journal of Obstetrics and Gynecology 179(1):186-193. doi: 
https://doi.org/10.1016/S0002-9378(98)70271-6 
Scifres, C. M., and D. M. Nelson. 2009. Intrauterine growth restriction, human placental 
development and trophoblast cell death. J Physiol 587(Pt 14):3453-3458. doi: 
10.1113/jphysiol.2009.173252 
Sedgh, G., S. Singh, and R. Hussain. 2014. Intended and unintended pregnancies worldwide in 
2012 and recent trends. Studies in family planning 45(3):301-314.  
Sharma, D., E. Aubry, T. Ouk, A. Houeijeh, V. Houfflin-Debarge, R. Besson, P. Deruelle, and L. 
Storme. 2017. Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid 
(DHA) on Fetal Pulmonary Circulation: An Experimental Study in Fetal Lambs. 
Nutrients 9(7)doi: 10.3390/nu9070761 
Smith, G., J. Savell, H. Dolezal, T. Field, D. Gill, D. Griffin, D. Hale, J. Morgan, S. Northcutt, 
and J. Tatum. 1995. The final report of the national beef quality audit. Colorado State 
Univ., Fort Collins  
Swanson, R. M., R. G. Tait, B. M. Galles, E. M. Duffy, T. B. Schmidt, J. L. Petersen, and D. T. 
Yates. 2020. Heat stress-induced deficits in growth, metabolic efficiency, and 
cardiovascular function coincided with chronic systemic inflammation and 
hypercatecholaminemia in ractopamine-supplemented feedlot lambs. Journal of Animal 
Science 98(6)doi: 10.1093/jas/skaa168 
Thorn, S., P. Rozance, L. Brown, and W. Hay. 2011. The Intrauterine Growth Restriction 
Phenotype: Fetal Adaptations and Potential Implications for Later Life Insulin Resistance 
and Diabetes. Seminars in Reproductive Medicine 29(03):225-236. doi: 10.1055/s-0031-
1275516 
Thorne, J., P. Downey, and E. E. Mooney. 2014. Placental pathology associated with small for 
gestational age infants. Ir Med J doi: 107(8): 249-50. 
Todros, T., A. Sciarrone, E. Piccoli, C. Guiot, P. Kaufmann, and J. Kingdom. 1999. Umbilical 
doppler waveforms and placental villous angiogenesis in pregnancies complicated by 









USDA. 2017. Overview of U.S. Livestock, Poultry, and Aquaculture Production in 2017. 
National Agricultural Statistics Service-USDA, National Agricultural Statistics Service-
USDA.  
Velten, M., R. D. Britt, K. M. Heyob, T. E. Tipple, and L. K. Rogers. 2014. Maternal Dietary 
Docosahexaenoic Acid Supplementation Attenuates Fetal Growth Restriction and 
Enhances Pulmonary Function in a Newborn Mouse Model of Perinatal Inflammation. 
The Journal of Nutrition 144(3):258-266. doi: 10.3945/jn.113.179259 
Wardinger, J. E., and S. Ambati. 2021. Placental Insufficiency. StatPearls [Internet]  
Weissman, C. 1990. The metabolic response to stress: an overview and update. Anesthesiology 
73(2):308-327. doi: 10.1097/00000542-199008000-00020 
Wu, G., F. W. Bazer, J. M. Wallace, and T. E. Spencer. 2006. BOARD-INVITED REVIEW: 
Intrauterine growth retardation: Implications for the animal sciences1. Journal of Animal 
Science 84(9):2316-2337. doi: 10.2527/jas.2006-156 
Yamada, N., J. Shimizu, M. Wada, T. Takita, and S. Innami. 1998. Changes in Platelet 
Aggregation and Lipid Metabolism in Rats Given Dietary Lipids Containing Different n-
3 Polyunsaturated Fatty Acids. Journal of Nutritional Science and Vitaminology 
44(2):279-289. doi: 10.3177/jnsv.44.279 
Yates, D. T., C. N. Cadaret, K. A. Beede, H. E. Riley, A. R. Macko, M. J. Anderson, L. E. 
Camacho, and S. W. Limesand. 2016. Intrauterine growth-restricted sheep fetuses exhibit 
smaller hindlimb muscle fibers and lower proportions of insulin-sensitive Type I fibers 
near term. Am J Physiol Regul Integr Comp Physiol 310(11):R1020-1029. doi: 
10.1152/ajpregu.00528.2015 
Yates, D. T., L. E. Camacho, A. C. Kelly, L. V. Steyn, M. A. Davis, A. T. Antolic, M. J. 
Anderson, R. Goyal, R. E. Allen, K. K. Papas, W. W. Hay, Jr., and S. W. Limesand. 
2019. Postnatal beta2 adrenergic treatment improves insulin sensitivity in lambs with 
IUGR but not persistent defects in pancreatic islets or skeletal muscle. J Physiol 
597(24):5835-5858. doi: 10.1113/JP278726 
Yates, D. T., D. S. Clarke, A. R. Macko, M. J. Anderson, L. A. Shelton, M. Nearing, R. E. Allen, 
R. P. Rhoads, and S. W. Limesand. 2014. Myoblasts from intrauterine growth-restricted 
sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller 
semitendinosus myofibres. The Journal of Physiology 592(14):3113-3125. doi: 
10.1113/jphysiol.2014.272591 
Yates, D. T., A. S. Green, and S. W. Limesand. 2011. Catecholamines mediate multiple fetal 
adaptations during placental insufficiency that contribute to intrauterine growth 
restriction: lessons from hyperthermic sheep. J Pregnancy 2011:740408. doi: 
10.1155/2011/740408 
Yates, D. T., J. L. Petersen, T. B. Schmidt, C. N. Cadaret, T. L. Barnes, R. J. Posont, and K. A. 
Beede. 2018. ASAS-SSR Triennnial Reproduction Symposium: Looking Back and 
Moving Forward—How Reproductive Physiology has Evolved: Fetal origins of impaired 
muscle growth and metabolic dysfunction: Lessons from the heat-stressed pregnant ewe1. 
Journal of Animal Science 96(7):2987-3002. doi: 10.1093/jas/sky164 
 
